Hormone clues behind severe PMS symptoms under investigation
NCT ID NCT07686718
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study looks at whether women with premenstrual dysphoric disorder (PMDD) have different levels of the hormones progesterone and estrogen in the week after ovulation compared to women without PMDD. Researchers will take a single blood sample about 7 days after ovulation and measure these hormone levels. The goal is to better understand the biological basis of PMDD, which could lead to improved diagnosis or treatments in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If differences are found, this could point toward better diagnosis or targeted treatments for PMDD.
- What could go wrong
- This is a small observational study, not a treatment trial. It may not find clear differences, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
adults of reproductive age who experience menstrual cycles and have a diagnosis of, or symptoms consistent with, Premenstrual Dysphoric Disorder (PMDD) or a control population
- Ages
-
18 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria * Aged 18-45 years old (adults but less than the typical perimenopausal age so there is not added bias/variable) * Regular menstrual cycles (21-35 days for the last 3 months) * Willing and able to complete a questionnaire (no new clinical diagnosis given) * Use home urine LH test strips to detect ovulation * Attend a single in person on site in Lancaster mid luteal blood test sample appointment (approx 7 days post LH surge) * Provide written informed consent * Have sufficient English language skills to understand the patient information * Be either in Group 1 or group 2 Group 1 (PMDD group ie case group) - self reported prior diagnosis of PMDD made by a healthcare professional (GP, psychiatrist, gynaecologist) Group 2 (Control group ie comparison group) - no prior diagnosis of PMDD made by a healthcare professional and no history of clinically significant premenstrual mood symptoms on screening Exclusion criteria * Current use or use in the last 3 months of hormonal contraception such as the combined oral contraceptive pill, the progestogen only pill, the implant, the injection, hormonal coil (Mirena, Kyleena) or patch/ring. * Current use or use in the last 3 months of any hormone replacement therapy (e.g. combined oestrogen and progesterone, oestrogen and Mirena coil combination, oestrogen alone if had a hysterectomy, or progesterone alone) or GnRH analogues use * On a selective serotonin reuptake inhibitor (SSRI) with a recent initiation or dose change within the last 3 months * Pregnant, breastfeeding or within 3 months post partum * Irregular menstrual cycles (outside the 21-35 day window) * Surgical menopause * Premature ovarian insufficiency * Other endocrine disorders e.g. uncontrolled thyroid disease, high prolactin, cushing's syndrome, polycystic ovarian syndrome) * Regular systemic steroid use or use of other medications known to affect sex hormone within the last 3 months * Severe mental health issues that impair consent or participation * Needle phobic so that venepuncture is intolerable * The use of the emergency contraceptive pill either 3 months prior to the study or during the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Premenstrual dysphoric disorder (PMDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Lancaster University
RECRUITINGLancaster, Lancashire, LA1 4YW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.